Full Press Release Details
Aurora Cannabis Appoints Dr. Jonathan
Page as Chief Science Officer
Promotes Dr. Shane Morris
to SVP Product Development and Regulatory Affairs
EDMONTON, Nov. 14, 2018 /CNW/ - Aurora Cannabis
Inc. (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce the appointment of Dr. Jonathan Page, PhD as the
Company's Chief Science Officer.
In this new role, Dr. Page will oversee all
science-related projects at the Company. The Aurora science team develops innovative products for the medical, wellness and adult
consumer markets and focuses on delivering industry-leading cultivation results in terms of yields, consistency, quality and efficiency.
Dr. Page is a globally renowned cannabis scientist,
with 37 peer-reviewed publications, who was the co-lead of the Canadian team of scientists who first sequenced the cannabis genome.
His work also helped discover the biochemical pathways leading to the major cannabinoids. Prior to his appointment, Dr. Page served
as CEO of recently acquired Anandia Labs, the world-leading cannabis-focused science company he co-founded.
"We are thrilled to have Jonathan join
the Aurora team as Chief Science Officer," said CEO Terry Booth. "Jonathan's knowledge of the cannabis plant and its
applications make him a globally recognized leader in the cannabis sector. With this appointment we are well-positioned to continue
to innovate through the research our teams are involved in and drive new commercial products."
Aurora has ingrained scientific methods throughout
the Company, which it uses to drive efficiencies, medical and plant discovery and product innovation. That approach will only increase
with Dr. Page's appointment. With more than 40 PhD- and MSc-level researchers, Aurora has cutting-edge research programs
designed to develop competitive advantages.
"Science is a critical to global competitiveness
and Aurora is the cannabis industry leader on this front," said Dr. Page. "Science is in Aurora's DNA. I'm very excited
to take on this new position and work with our science teams to take the development of the cannabis plant and its applications
An entrepreneurial scientist, Dr. Page co-founded
Anandia Labs, which specializes in cannabis genetics, metabolite profiling, plant breeding, disease characterization, and cultivar
certification, as well as providing third party independent testing services to producers and patient-cultivators. Dr. Page is
an adjunct professor in the Botany Department at the University of British Columbia (UBC) who received his PhD from UBC, undertook
postdoctoral training in Germany, and for a decade directed a lab at the National Research Council. Dr. Page is also an accomplished
inventor with eight issued patents or patent applications, and a frequent lecturer on cannabis science at international conferences.
Anandia will continue to operate independently
of Aurora. Dr. John Coleman, PhD will be taking over as President at Anandia.
Dr. Shane Morris promoted to SVP Product
Development and Regulatory Affairs
Aurora is also pleased to announce the promotion
of Dr. Shane Morris, PhD to the role of Senior Vice-President of product development and regulatory affairs. Dr. Morris had been
the Vice-President in this role previously.
"Innovation and consumer focused products
will be critical for future success in the global cannabis sector," said Dr. Shane Morris. "Discovery, technical skills,
quality excellence and regulatory expertise all need to be integrated in order to develop and successfully introduce those products
that the global markets are looking for. Building a collaborative global team that can execute across these areas and turn ideas
into revenue is what sets Aurora apart as a world leader in the cannabis industry."
Dr. Morris and his team are responsible for
numerous product innovations at Aurora, including the recent launch of Aurora Cloud, the industry's only vape-ready CBD oil cartridge
available on the Canadian medical cannabis market.
"Shane's promotion is based on his incredible
track record that has positioned Aurora's leading product development team at the cutting edge of our industry," said CEO
Terry Booth. "Shane has delivered and proven time and again that he is exceptionally well suited to lead this function."
Headquartered in Edmonton, Alberta, Canada
with funded capacity in excess of 500,000 kg per annum and sales and operations in 20 countries across five continents, Aurora
is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across
every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis
and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora
has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate
leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale
production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are
designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.
Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf
Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.
In addition to Aurora's rapid organic growth
and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf, CanvasRX,
Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC - Aurora is distinguished
by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),
Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and
NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit
our investor website, investor.auroramj.com.
Forward looking statements
This news release includes statements containing
certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may", "will",
"potential", "proposed" and other similar words, or statements that certain events or conditions "may"
or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties
and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services
Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy
Aurora Cannabis Inc.
original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-appoints-dr-jonathan-page-as-chief-science-officer-300750502.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia:
For further information: MEDIA CONTACTS: Heather MacGregor,
Director of Communications, Aurora Cannabis, M : (416) 509-5416, heather.macgregor@auroramj.com, www.auroramj.com; Nicole Lascelle,
Gestionnaire des Relations, communautaires et communications, Community Relations & Communications Manager, M : (438) 828-4834,
Nicole.lascelle@auroramj.com, www.auroramj.com; INVESTOR RELATIONS: Marc Lakmaaker, Vice President, Investor Relations, Aurora
Cannabis, M: (647) 269-5523, marc.lakmaaker@auroramj.com, www.auroramj.com; Rob Kelly, Director, Investor Relations, M: (647) 331-7228,
CO: Aurora Cannabis Inc.
CNW 13:00e 14-NOV-18